Statins, inhibitors of
3-hydroxy-3-methylglutaryl-coenzyme A reductase, are a well-known class of
drug with beneficial
therapeutic effects in
cardiovascular disease and
lipid disorders and have potential use against
cancer. However, the bioavailability of
statins is hampered due to low aqueous solubility and rapid metabolism. To improve pharmacokinetic profiles of
statins, development of drug delivery systems is promising. Hence, the use of
liposomes for selective delivery of
statins to a selected site or for bioavailability enhancement is an effective strategy to increase
statin therapeutic effects. Moreover, liposomal delivery can reduce the required dose of
statins especially in terms of antitumor effects.
Liposomes, because of their unique properties and biphasic and amphiphilic nature, have attracted much interest and can be considered as a suitable choice for delivery of both hydrophilic and lipophilic
statins. In this review article, we focus on
liposomes and evaluate the effects of different liposomal delivery systems, based on differences in size,
phospholipid composition, circulation half-life, and
cholesterol content, on
statin function.